News | December 18, 2023
Biocon Biologics concludes integration of acquired Biosimilars business in 120 countries
10+ emerging markets, Japan & ANZ transition in final phase
10+ emerging markets, Japan & ANZ transition in final phase
This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
Laurus Synthesis receives Form 483 with 5 observations from USFDA
Fischer Chemic will make an entry into the growing market of diagnostic imaging industry with innovative and disruptive technologies
Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list
Receives registration of Valganciclovir powder for oral solution in Germany
Expands patient reach to remotest towns by furthering investment in GoApptiv
Expansion of presence in India with electrical safety, electromagnetic compatibility and medical device biocompatibility, toxicity and microbiology testing and certification services
The company makes its maiden entry into Azerbaijan’s pharmaceutical market
Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid
Subscribe To Our Newsletter & Stay Updated
